Combined Application of Bevacizumab and Pd-1 Blockade Displays Durable Treatment Effects by Increasing the Infiltration And Cytotoxic Function of Cd8 + T Cells in Lung Cancer

• DOI: 10.2217/imt-2021-0196
• Publication Date: 2022-05-16T07:43:02Z
• Authors: Yanxia Liu; Tongmei Zhang; Lina Zhang; Cong Zhao; Zhiyun Zhang; Ziyu Wang; Meng Gu; Weiying Li; Baolan Li
• Keywords: 0301 basic medicine; Lung Neoplasms; Programmed Cell Death 1 Receptor; CD8-Positive T-Lymphocytes; 3. Good health; Bevacizumab; Mice, Inbred C57BL; Mice; 03 medical and health sciences; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Antineoplastic Combined Chemotherapy Protocols; Tumor Microenvironment; Animals; Humans; Immune Checkpoint Inhibitors

Aim: VEGF/VEGFR inhibitors may help immune checkpoint expand the population that will benefit from treatment. The authors investigated efficacy of combined bevacizumab and PD-1 antibody. Materials & methods: C57BL/6J mice were injected subcutaneously with 1 × 106 Lewis lung carcinoma cells. intraperitoneally 0.25 mg anti-PD-1 and/or 15 mg/kg bevacizumab. Tumor tissues harvested. reported a non-small cell cancer patient received 200 antibody 7.5 as fourth-line Results: Bevacizumab induced strong durable antitumor effect. improved abnormal tumor vessels enhanced cytotoxic function infiltration T lymphocytes. patient's survival time was significantly prolonged. Conclusion: induces effect by increasing CD8+ cells in cancer.